Treatment approach for transplant ineligible patients. Dara‐VRd,... | Download Scientific Diagram
Vincent Rajkumar on X: "Impressive results with Dara-VRd in newly diagnosed myeloma presents by Dr. Peter Voorhees. #ASH19. Await phase III PERSEUS. Will consider this regimen for transplant eligible high risk myeloma.
How I treat relapsed multiple myeloma - ScienceDirect
ASH23: Daratumumab (DARA) + Bortezomib, Lenalidomide, & Dexamethasone (VRd) vs Vrd Alone: Primar...
Vincent Rajkumar on X: "Our myeloma & amyloidosis guidelines have been updated. https://t.co/XG65zjBWog @MayoMyeloma Key changes this year are listed below. 1/ For newly diagnosed myeloma we added Dara-Rd as alternative to
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM
Vincent Rajkumar on X: "2) VRd is still included as a reasonable alternative for standard risk patients since we do not have data that OS is improved with Dara VRd compared to
PERSEUS: Primary efficacy and safety results
Multiple myeloma current treatment algorithms | Blood Cancer Journal
Perseus Study - EMN 17 - Multiple Myeloma Clinical Trials
Multiple myeloma with high-risk cytogenetics and its treatment approach | International Journal of Hematology
PERSEUS: Daratumumab plus VRd in Newly Diagnosed Multiple Myeloma Patients
PERSEUS: Dara-VRd vs VRd in Patients with NDMM Eligible for Autologous Stem Cell Transplantation
Cancers | Free Full-Text | Recent Advances in the Treatment of Patients with Multiple Myeloma
Ben Derman on X: "Peter Vorhees updated results from GRIFFIN study (Dara/VRd vs. VRd). sCR 42.4% vs 32% (HR 1.57 with 95% CI: 0.87 - 2.82, p=0.1359, which exceeded pre-set 2-sided alpha
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. - Abstract - Europe PMC
ASH23: Daratumumab (DARA) + Bortezomib, Lenalidomide, & Dexamethasone (VRd) vs Vrd Alone: Primary Results of the Perseus Trial
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
EMN17 - European Myeloma Network
Aiming for the cure in myeloma: Putting our best foot forward - ScienceDirect
Perseus Study - EMN 17 - Multiple Myeloma Clinical Trials
Phase 3 Perseus Trial in Patients Eligible for ASCT | Int'l Myeloma Fn
Study design. Abbreviations: VRd: Bortezomib, lenalidomide,... | Download Scientific Diagram
